Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biosimilar Draft Guidance Outlines Three-Arm Bridging Studies For Non-U.S. Products

This article was originally published in The Pink Sheet Daily

Executive Summary

Clinical pharmacology data could help biosimilar sponsors pursue a more global development plan.

You may also be interested in...



Biosimilars: FDA Closes Out 2016 With Clinical Pharmacology Guidance

While industry awaits US FDA guidance on interchangeability, agency finalizes document on clinical pharmacology data to support a demonstration of biosimilarity – years ahead of May 2019 target date in commitment letter for user fee program's renewal.

Biosimilars: FDA Closes Out 2016 With Clinical Pharmacology Guidance

While industry awaits US FDA guidance on interchangeability, agency finalizes document on clinical pharmacology data to support a demonstration of biosimilarity – years ahead of May 2019 target date in commitment letter for user fee program's renewal.

Biosimilars: FDA’s Four-Tiered Assessment Draws Industry Scrutiny

PhRMA asks FDA to remove the categorization of a product as not similar, similar, highly similar, or similar with fingerprint-like similarity.

Related Content

Topics

UsernamePublicRestriction

Register

PS077199

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel